Lipocine announces lpcn 1154 meets bioequivalence with iv brexanolone in pivotal study

Met standard bioequivalence (be) criteria cmax, auc0-t, and auc 0- ∞ ctrough criterion was met lpcn 1154 was well tolerated with no sedation or somnolence events observed on track for nda filing, targeted by end of q4 2024 salt lake city , june 25, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive topline study results demonstrating bioequivalence of lpcn 1154 to iv brexanolone in an nda enabling pivotal pharmacokinetic (pk) study.  lipocine is developing lpcn 1154, oral brexanolone, for the treatment of postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking